Difference between revisions of "Team:Oxford/Description"

Line 39: Line 39:
 
                         <div class="quote quote-right">
 
                         <div class="quote quote-right">
 
                             <p>
 
                             <p>
−
                                 "No action today means no cure tomorrow."
+
                                 "Years from now we will treat most infections with bacteria and not antibiotics."
 
                             </p>
 
                             </p>
−
                             <h3>Dr Margaret Chan<br>WHO Director General, 2011</h3>
+
                             <h3>Professor James Malone-Lee<br>Barlow Professor of Geriatric Medicine</h3>
 
                         </div>
 
                         </div>
 
                         <p>
 
                         <p>
−
                             Antimicrobial resistance is a complex problem driven by many interconnected factors. As such, single, isolated interventions have little impact. Coordinated action is required to minimize emergence and spread of antimicrobial resistance. The aim of our project is to contribute to the growing body of research into providing a solution to the threat of antimicrobial resistance.
+
                             A solution is urgently needed for the increasing number of infections caused by antibiotic-resistant bacteria. The engineering of bacterial cells to fight human pathogens is a promising alternative to administering traditional antibiotics. Our project involves the use of synthetic biology to engineer living therapeutics that have the potential to treat urinary tract infections (UTIs), which are a major public health concern in developed countries. This is largely due to growing antimicrobial resistance (AMR).
 
                         </p>
 
                         </p>
 +
                    </div>
 +
                </div>
 +
                <div class="section" id="problem">
 +
                    <div class="slim">
 +
                        <h2>The problem</h2>
 +
                        <ul>
 +
                            <li>Antibiotics have negative side effects and antimicrobial resistance is a growing problem</li>
 +
                            <li>UTIs are the most common hospital-acquired infection and the bacteria that cause them are frequently resistant to antimicrobials</li>
 +
                            <li>AMR in UTIs is caused by biofilms</li>
 +
                            <li>Biofilms are currently estimated to be responsible for over 65% of all hospital-acquired infections</li>
 +
                            <li>Current UTI treatments are ineffective and fail to prevent recurrent infections</li>
 +
                        </ul>
 +
                    </div>
 +
                </div>
 +
                <div class="section" id="antibio">
 +
                    <div class="slim">
 +
                        <h3>Problem with antibiotics</h3>
 
                         <p>
 
                         <p>
−
                             The World Health Organisation have recently (May 2015) endorsed a global action plan to tackle antimicrobial resistance.
+
                             Antibiotic use is associated with numerous negative side effects, allergies and reactions. The most common side effects of antibiotics all impact the digestive system and occur in around one in ten people. Around one person in fifteen has an allergic reaction to antibiotics, especially penicillin and cephalosphorins [10]. Half of the patients we spoke to during our project wanted us to find an alternative to using antibiotics, owing to the severity of the negative side effects that they experience.
 
                         </p>
 
                         </p>
 
                         <p>
 
                         <p>
−
                             The plan sets out 5 objectives:
+
                             Despite their negative side effects, antibiotics have been used so widely and for so long that the targeted microbes have adapted to become resistant, reducing the effectiveness of the drugs. A vicious cycle ensues in which ineffective antibiotic treatments leads to overprescription and overexposure, which amplifies the problem of AMR. Global antibiotic consumption grew by 30% between 2000 and 2010. [27] Described by the Chief Medical Officer of England as “a threat equal to that of terrorism”, the growing resistance to antibiotics is hindering the effective prevention and treatment of an ever increasing range of infections.
 
                         </p>
 
                         </p>
−
                         <ol>
+
                         <div class="quote quote-full">
−
                             <li><p>Improve awareness and understanding of antimicrobial resistance</p></li>
+
                             <p>
−
                            <li><p>Strengthen surveillance and research</p></li>
+
                                Antimicrobial resistance poses a catastrophic threat. If we don't act now, any one of us could go into hospital in 20 years for minor surgery and die because of an ordinary infection that can't be treated by antibiotics.
−
                            <li><p>Reduce the incidence of infection</p></li>
+
                             </p>
−
                             <li><p>Optimize the use of antimicrobial medicines</p></li>
+
                             <h3>Professor Dame Sally Davies<br>Chief Medical Officer<br>March 2013</h3>
−
                             <li><p>Ensure sustainable investment in countering antimicrobial resistance</p></li>
+
                         </div>
−
                         </ol>
+
 
                         <p>
 
                         <p>
−
                             Our solution considers the first two objectives of this plan: human practices to improve education and awareness of the problem that antibiotic resistance poses and laboratory work to further research into finding alternatives to administering antibiotics. We want to use synthetic biology to provide a solution.
+
                             The World Health Organisation’s (WHO) antimicrobial resistance Global Report on Surveillance, reports increasing worldwide incidences of AMR, in particular antibacterial resistance (ABR). This highlights very high rates of resistance in bacteria that cause common healthcare associated and community-acquired infections, such as UTIs [1]. UTIs account for over 7 million doctor visits per year. Catheter associated UTIs (CAUTIs) are the most commonly acquired infection in hospitals, and there is a high incidence of ABR in the bacteria that cause UTIs globally [2].
 
                         </p>
 
                         </p>
 +
                    </div>
 +
                </div>
 +
                <div class="section" id="biofilms">
 +
                    <div class="slim">
 +
                        <h2>Biofilms</h2>
 
                         <p>
 
                         <p>
−
                             Although bacteria are generally thought of as causing infection, most bacteria that live inside the human body are non-pathogenic and some of them can be turned, after proper engineering, into ‘smart’ living therapeutics that have the potential to treat a diverse range of diseases. We are focused specifically on treating UTIs and, by employing the power of engineered E. coli, we are creating a system that offers persistent protection against biofilm formation in the urinary tract and on the surface of catheters without the use of antibiotics.
+
                             Biofilms are aggregates of surface-associated microorganisms that are encased in a matrix of highly-hydrated extracellular polymeric substances (EPS), which include extracellular polysaccharides, extracellular DNA, as well as proteins [6]. Van Leeuwenhoek, using his simple microscopes in 1684, first observed microorganisms on tooth surfaces and can be credited with the discovery of microbial biofilms. "The number of these animalcules in the scurf of a man's teeth are so many that I believe they exceed the number of men in a kingdom." - Leeuwenhoek
 
                         </p>
 
                         </p>
−
                         <div id="overview-what">
+
                         <p>
−
                             <h3>What?</h3>
+
                            We now know a great deal more about biofilms. Environmental changes are responsible for the transition from planktonic growth to biofilm [13] and cause changes in the expression of surface molecules, virulence factors, and metabolic status. This allows the bacteria to acquire properties that enable their survival in unfavourable conditions [14,15], such as in the presence of antibiotics. The low nutrient and oxygen levels at the bottom of the biofilm give rise to metabolically-inactive bacteria. As such, these persister cells are rendered unsusceptible to most traditional antibiotics, which rely on bacterial metabolism to exert cell-killing effect [7].
 +
                        </p>
 +
                    </div>
 +
                </div>
 +
                <div class="section" id="utis">
 +
                    <div class="slim">
 +
                        <h2>UTIs</h2>
 +
                        <p>
 +
                            Biofilms are currently estimated to be responsible for over 65% of nosocomial infections and 80% of all microbial infections [16]. Bacterial biofilms play an important role in UTIs. UTIs are caused by the pathogenic invasion of the urinary tract, which causes an inflammatory response of the urothelium. It is estimated that approximately 40% of women have had a UTI at some time in their lives [10]. UTIs may be caused by a variety of different organisms, most commonly bacteria. The most frequent cause of UTI in adult women is <em>Escherichia coli</em>, accounting for approximately 85% of community-acquired UTIs and 25-50% of hospital-acquired UTIs. Nosocomial infections may involve more aggressive organisms such as <em>Pseudomonas aeruginosa</em> and <em>Enterobacter</em> species.
 +
                        </p>
 +
                    </div>
 +
                </div>
 +
                <div class="section" id="solution">
 +
                    <div class="slim">
 +
                        <h2>The Solution</h2>
 +
                        <ul>
 +
                            <li>Break down bacterial biofilms to liberate the bacteria encased within and reduce the dose of antibiotics required</li>
 +
                            <li>Breaking down bacterial biofilms and kill the bacteria encased within to provide an alternative to antibiotics</li>
 +
                        </ul>
 +
                    </div>
 +
                    <div id="solution-overview">
 +
                        <div class="slim">
 +
                            Our solution is focused on providing a treatment for UTIs because conventional antibiotics are unable to treat these and other biofilm-associated infections. Given the prevalence of such infections, there is a growing need for alternative therapeutic agents that can specifically degrade biofilms and kill the bacteria encased within. The use of synthetic biology to produce enzymes is the most effective way to achieve this specificity based on current technology. Our solution aims to investigate how bacterial biofilm disrupting proteins and antimicrobial proteins can be exported from <em>E. coli</em> and subsequently retain their antibiofilm/antimicrobial function. Using this secretion device we seek to create a system that offers persistent protection against biofilm formation.
 +
                        </p>
 +
                        <p>
 +
                            We have designed a device that can exert antibiofilm and antibacterial activity against <em>E. coli</em> and <em>P. aeruginosa</em>, the two leading causes of CAUTIs [4]. A nonpathogenic laboratory strain of <em>E. coli</em> is used as the expression host for the production of these enzymes as a proof-of-concept. The antibiofilm enzymes that we are using are Dispersin B and Micrococcal DNase, and the antibacterial proteins that we are using are Art-175 and Microcin S.
 +
                        </p>
 +
                        </div>
 +
                    </div>
 +
                    <div id="solution-degrading-biofilm">
 +
                        <div class="slim">
 +
                             <h3>Degrading the biofilm</h3>
 
                             <p>
 
                             <p>
−
                                 The threat of antimicrobial resistance is a serious global public health concern. One of the ways bacteria protect themselves against antimicrobial drugs is by growing biofilms. The biological definition for a biofilm: “an assemblage of surface-associated microorganisms that secrete a mucilaginous protective coating in which they are encased.” Van Leeuwenhoek, using his simple microscopes, first observed microorganisms on tooth surfaces and can be credited with the discovery of microbial biofilms. These bacterial slimes are responsible for a whole host of medical, industrial and environmental problems that are very costly and technically challenging to remedy. Biofilms are involved in catheter and implant infections, dental plaque formation as well as infections in cystic fibrosis patients.  Biofilm can be found in the urothelium, prostate stones, and implanted foreign bodies. In industry and infrastructure, biofilms are also the main culprit behind the fouling of various plants and pipelines for aquaculture, water treatment, and food production.
+
                                 Prof. Malone-Lee stressed to us that sensitivity is a greater problem than complete antimicrobial resistance. “Many more strains of bacteria are just insensitive to low doses of antibiotics, many can be overcome by high doses over long periods of time. Resistance is definitely not absolute.” Breaking down the biofilm increases the sensitivity of the bacteria embedded within it. Planktonic bacteria are metabolically active and are thus prone to antibiotics, meaning that lower doses are required.
 
                             </p>
 
                             </p>
 
                             <p>
 
                             <p>
−
                                 Our solution is focused on providing a treatment for urinary tract infections (UTIs). 90% of urinary infections are caused by uropathogenic E. coli (UPEC) and the biofilm that they form in the urinary tract. Resistance to one of the most widely used antibacterial drugs for the oral treatment of urinary infections caused by E. coli – fluoroquinolones – is now widespread and, with UTIs being the most commonly acquired infection at hospital, there is a huge need to find a solution for the treatment of UTIs and resistance to antimicrobial resistance.
+
                                 DspB (<a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1659200">BBa_K1659200</a>) is an enzyme produced by <em>Aggregatibacter actinomycetemcomitans</em>, a species of bacteria found in the human oral cavity that grows almost exclusively in the form of biofilms. Structural analysis of Dispersin B showed that the enzyme only works specifically against the β-1,6-glycosidic linkages found in poly-N-acetylglucosamine (PGA), which is a polysaccharide structural element found in the biofilms of <em>E. coli</em> but not in <em>P. aeruginosa</em>. An additional enzyme would need to be used to target the polysaccharide component of <em>P. aeruginosa</em> biofilms.
 
                             </p>
 
                             </p>
 
                             <p>
 
                             <p>
−
                                 <em>See UTIs facts and figures for more information.</em>
+
                                 Micrococcal DNase (<a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1659300">BBa_K1659300</a>) is an endo-exonuclease that non-specifically catalyzes the hydrolysis of single- and double-stranded DNA under basic conditions and in the presence of Ca2+ ions, and is known to be able to speed up DNA hydrolysis by up to 1016 times [17]. We are using DNase to break down the extracellular DNA component of biofilms.
 
                             </p>
 
                             </p>
 +
                        </div>
 +
                    </div>
 +
                    <div id="solution-killing-bacteria">
 +
                        <div class="slim">
 +
                            <h3>Killing the bacteria</h3>
 
                             <p>
 
                             <p>
−
                                 Both antimicrobial resistance and the other problems associated with biofilm formation are big issues in their own right but are especially problematic when they’re combined. The bacteria, already constantly evolving to afford themselves more innate resistance against antibiotics, produce biofilms as protective layers that shield them from the drugs even more comprehensively.
+
                                 Although ABR is not absolute, it does pose a very big threat to the effective treatment of many infections. The insensitivity of bacteria to antibiotics can also be attributed to the increasing ABR. As described above, antibiotics also have many side effects that reduce patient quality of life and decrease the likelihood of completing a course of antibiotics. With all of this in mind, our solution does not only break down the biofilm, but also kills the bacteria embedded within so as to provide an alternative to antibiotics.
 
                             </p>
 
                             </p>
−
                        </div>
+
                            <div id="solution-killing-bacteria-art175">
−
                        <div id="overview-why">
+
                                 <h4>Art-175</h4>
−
                            <h3>Why?</h3>
+
−
                            <ul>
+
−
                                 <li>UTIs are the most common nosocomial infection</li>
+
−
                                <li>There is growing resistance to the antibiotics currently used to treat urinary infections</li>
+
−
                                <li>Biofilms are major problem both in health and industry </li>
+
−
                                <li>Antibiotics have a negative effect on the beneficial gut flora</li>
+
−
                                <li>There is a current failure to prevent recurrent infections</li>
+
−
                            </ul>
+
−
                            <div class="quote quote-full">
+
 
                                 <p>
 
                                 <p>
−
                                     "Antimicrobial resistance poses a catastrophic threat. If we don't act now, any one of us could go into hospital in 20 years for minor surgery and die because of an ordinary infection that can't be treated with antibiotics."
+
                                     Art-175 (<a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1659000">BBa_K1659000</a>) derive their name from “artificial endolysins”. Endolysins are bacteriophage-encoded peptidoglycan hydrolases that pass through the cytoplasmic membrane, degrading the peptidoglycan layer and inducing the lysis of the infected cell.
 +
                                </p>
 +
                            </div>
 +
                            <div id="solution-killing-bacteria-mccs">
 +
                                <h4>MccS</h4>
 +
                                <p>
 +
                                    MccS (<a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1659100">BBa_K1659000</a>) is a type of microcin, a subclass of antibacterial proteins known as bacteriocins. Microcins are small, enterobacteria-produced bacteriocins that exert antibacterial activity against closely-related species, and MccS is produced by E. coli present in the probiotic drug Symbioflor 2 that has been shown to successfully treat gastrointestinal disorders.
 +
                                </p>
 +
                                <p>
 +
                                    For more information, please visit our <a href="https://2015.igem.org/Team:Oxford/Parts">Parts</a> page.
 
                                 </p>
 
                                 </p>
−
                                <h3>Professor Dame Sally Davies<br>Chief Medical Officer, March 2013</h3>
 
 
                             </div>
 
                             </div>
−
                        </div>
 
−
                        <div id="overview-how">
 
−
                            <h3>How?</h3>
 
 
                             <p>
 
                             <p>
−
                                 There is currently no commercial antibiotic that specifically targets bacterial biofilms, but researchers have identified a range of bacterially-derived biomolecules that degrade and destroy biofilms. Our solution aims to investigate how bacterial biofilm disrupting proteins and antimicrobial proteins can be exported from E. coli.
+
                                 Current clinically-relevant pathogens have not been seen to exhibit resistance against our antibacterial proteins of choice. Art-175 has been experimentally shown to be not susceptible to resistance development, likely because it targets the structural element of the bacterial cell wall that is highly conserved across species and difficult to mutate [8]. The mechanism by which Microcin S exerts antibacterial activity is still currently unknown, but no bacterial strains except for the original strain of probiotic E. coli which produces Microcin S has been shown to be resistant to it thus far [9].
 
                             </p>
 
                             </p>
 +
                        </div>
 +
                    </div>
 +
                    <div id="solution-secreting">
 +
                        <div class="slim">
 +
                            <h3>Secreting the proteins</h3>
 
                             <p>
 
                             <p>
−
                                 The proteins DispersinB, MicrocinS, DNase and Endolysin will be fused with secretion tags to target them to normal bacterial secretion pathways. By hijacking the natural processes by which E. coli secrete proteins, we can target our anti-biofilm agents out of E. coli and onto a biofilm infected surface. Additionally, our E. coli will lyse upon sensing the presence of a biofilm, releasing a pulse of proteins from the cytoplasm on detection of a high target cell density.
+
                                 The proven secretion of folded, functional proteins across both bacterial cell membranes is a challenge for present day microbiologists. Our solution requires that we can export DspB, DNase, Art-175 and MccS out of the expression host and into the local biofilm environment. To achieve this, signal sequences are fused to the enzymes to target them for export through natural E. coli secretion pathways. Using this mechanism we can direct our anti-biofilm and antimicrobial agents at a biofilm infected surface as they are being produced.
−
                            </p>
+
−
                            <p>
+
−
                                The beauty of the anti-biofilm agents we plan to use is that they have been shown not to induce resistance in the target bacteria, meaning that having them continually produced at a low level will not be nearly bad as with traditional antibiotics. Our system is applicable to a whole host of biofilm environments and with a simple design that can be used in multiple sectors, we hope to get a step further in providing a novel approach to treating microbial infections. In terms of product formulation and design, we hope to ultimately arrive at a functional proof-of-concept e.g. an enzyme-secreting infection-clearing catheter or a modular system that continuously and cheaply cleans out pipelines.
+
 
                             </p>
 
                             </p>
 +
                            <div id="solution-sectreting-dsba">
 +
                                <h4>DsbA</h4>
 +
                                <p>
 +
                                    DsbA is a oxidoreductase protein found predominantly in Gram-negative bacteria, which functions as a protein-folding factor [19][20]. The 2-19 peptide sequence of DsbA is a signal sequence that can direct passenger proteins for co-translational export via the signal recognition particle (SRP) pathway [21][22]. It has recently been shown that the DsbA signal sequence is capable of mediating passenger protein secretion under a selection of different induction temperatures [23].
 +
                                </p>
 +
                                <p>
 +
                                    Parts:  <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1659002">BBa_K1659002</a>, <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1659201">BBa_K1659201</a>,<a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1659301">BBa_K1659301</a>
 +
                                </p>
 +
                            </div>
 +
                            <div id="solution-sectreting-yebf">
 +
                                <h4>YebF</h4>
 +
                                <p>
 +
                                    YebF is a 13kDa protein of unknown function that is perhaps the only protein that has been conclusively documented to be secreted into the extracellular medium by a laboratory E. coli strain. At the N-terminus, YebF has a 2.2 kDa sec-leader sequence which mediates its translocation through the bacterial inner membrane via the Sec pathway, and is cleaved upon translocation into the periplasm to give the 10.8 kDa "mature" form [24]. Export from periplasm into the extracellular space takes places via the Omp pathway. YebF has been used successfully to mediate the secretion of recombinant proteins [25][26].
 +
                                </p>
 +
                                <p>
 +
                                    Part: <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1659003">BBa_K1659003</a>
 +
                                </p>
 +
                            </div>
 +
                            <div id="solution-secreting-fla">
 +
                                <h4>Fla</h4>
 +
                                <p>Flagellin are the constituent subunits of the helical filament substructure of bacterial flagella. In the flagellar-building process, flagellin are exported out of the cell sequentially by the flagellum-specific export apparatus. F. Vonderviszt et al. demonstrated through their work that the signal sequence responsible for allowing the flagellar export system to identify and export Salmonella flagellin is its 26-47 amino acid residue segment [18].</p>
 +
                                <p>
 +
                                    Part: <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1659001">BBa_K1659001</a>
 +
                                </p>
 +
                            </div>
 
                         </div>
 
                         </div>
 
                     </div>
 
                     </div>
 +
                </div>
 +
                <div class="section" id="results">
 +
                    <div class="slim">
 +
                        <h2>Results</h2>
 +
                        <div id="results-antimicrobials">
 +
                            <h3>Antimicrobials</h3>
 +
                            <div id="results-antimicrobials-art175">
 +
                                <h4>Art-175</h4>
 +
                            </div>
 +
                            <div id="results-antimicrobials-mccs">
 +
                                <h4>MccS</h4>
 +
                            </div>
 +
                        </div>
 +
                        <div id="results-antibiofilms">
 +
                            <h3>Antibiofilms</h3>
 +
                            <div id="results-antimicrobials-dspb">
 +
                                <h4>DspB</h4>
 +
                            </div>
 +
                        </div>
 +
                    </div>
 +
                </div>
 +
                <div class="section" id="conclusion">
 +
                    <div class="slim">
 +
                        <h2>Conclusion</h2>
 +
                    </div>
 +
                </div>
 +
                <div class="section" id="future">
 +
                    <div class="slim">
 +
                        <h2>Future</h2>
 +
                        <p>
 +
                            Our modelling of diffusion out of the biobeads showed that we would need too great a number of biobeads for this to be realistic design approach. To overcome this problem we would need unrealistically efficient enzymes or unrealistically high protein synthesis rates. The other way around this is to create a system that provides a high local concentration of antibiofilm/antimicrobial agents at the point that is needed.
 +
                        </p>
 +
                    </div>
 +
                </div>
 +
                <div id="references">
 +
                    <h2>References</h2>
 +
                    <ol class="references">
 +
                        <li>Global Report on Surveillance of Antimicrobial Resistance: 2014. WHO.</li>
 +
                        <li>Johnson, J.R., 2004. Laboratory diagnosis of urinary tract infections in adult patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 39(6), p.873; author reply 873–874.</li>
 +
                        <li>Zalewska-Piatek, B. et al., 2013. Biochemical characteristic of biofilm of uropathogenic Escherichia coli Dr+ strains. Microbiological Research, 168, pp.367–378.</li>
 +
                        <li>Sievert, D.M. et al., 2013. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America, 34(1), pp.1–14. Available at: <a href="http://www.ncbi.nlm.nih.gov/pubmed/23221186">http://www.ncbi.nlm.nih.gov/pubmed/23221186</a>.</li>
 +
                        <li>Fux, C. a. et al., 2005. Survival strategies of infectious biofilms. Trends in Microbiology, 13(1), pp.34–40.</li>
 +
                        <li>Flemming, H.-C. & Wingender, J., 2010. The biofilm matrix. Nature reviews. Microbiology, 8(9), pp.623–633. Available at: <a href="http://dx.doi.org/10.1038/nrmicro2415">http://dx.doi.org/10.1038/nrmicro2415</a>.</li>
 +
                        <li>Høiby, N. et al., 2010. Antibiotic resistance of bacterial biofilms. International Journal of Antimicrobial Agents, 35(4), pp.322–332.</li>
 +
                        <li>Briers, Y. et al., 2014. Art-175 is a highly efficient antibacterial against multidrug-resistant strains and persisters of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 58(7), pp.3774–3784.</li>
 +
                        <li>Gunzer, F., 2013. Bacterially-formed microcin S, a new antimicrobial peptide, effective against pathogenic microorganisms, e.g. enterohaemorrhagic Escherichia coli (EHEC), European Patent EP2557163A1.</li>
 +
                        <li>Antibiotics - Side effects. Avaolable from: <a href="http://www.nhs.uk/Conditions/Antibiotics-penicillins/Pages/Side-effects.aspx">http://www.nhs.uk/Conditions/Antibiotics-penicillins/Pages/Side-effects.aspx</a> [5/06/2015]</li>
 +
                        <li>C. M. Kunin, “Urinary tract infections in females,” Clinical Infectious Diseases, vol. 18, no. 1, pp. 1–12, 1994.</li>
 +
                        <li>J. W. Warren, “Catheter-associated urinary tract infections,” Infectious Disease Clinics of North America, vol. 11, no. 3, pp. 609–622, 1997</li>
 +
                        <li>A. P. Lenz, K. S. Williamson, B. Pitts, P. S. Stewart, and M. J. Franklin, “Localized gene expression in Pseudomonas aeruginosa biofilms,” Applied and Environmental Microbiology, vol. 74, no. 14, pp. 4463–4471, 2008.</li>
 +
                        <li>L. Zhang and T. Mah, “Involvement of a novel efflux system in biofilm-specific resistance to antibiotics,” Journal of Bacteriology, vol. 190, no. 13, pp. 4447–4452, 2008.</li>
 +
                        <li>J. Klebensberger, A. Birkenmaier, R. Geffers, S. Kjelleberg, and B. Philipp, “SiaA and SiaD are essential for inducing autoaggregation as a specific response to detergent stress in Pseudomonas aeruginosa,” Environmental Microbiology, vol. 11, no. 12, pp. 3073–3086, 2009</li>
 +
                        <li>U. Römling and C. Balsalobre, “Biofilm infections, their resilience to therapy and innovative treatment strategies,” Journal of Internal Medicine, vol. 272, no. 6, pp. 541–561, 2012</li>
 +
                        <li>Hale, S.P., Poole, L.B. & Gerlt, J. a, 1993. Mechanism of the reaction catalyzed by staphylococcal nuclease: identification of the rate-determining step. Biochemistry, 32(29), pp.7479–7487</li>
 +
                        <li>Vondervizst, F., Sajó, R., Dobó, J., & Závodszky, P. (2012). The Use of a Flagellar Export Signal for the Secretion of Recombinant Proteins in Salmonella. In: Recombinant Gene Expression - Reviews and Protocols, Methods in Molecular Biology, 824, 131-143.</li>
 +
                        <li>Guddat, L.W., Bardwell, J.C. & Martin, J.L., 1998. Crystal structures of reduced and oxidized DsbA: investigation of domain motion and thiolate stabilization. Structure (London, England : 1993), 6(6), pp.757–767.</li>
 +
                        <li>Heras, B. et al., 2009. DSB proteins and bacterial pathogenicity. Nature reviews. Microbiology, 7(3), pp.215–225.</li>
 +
                        <li>Schierle, C.F. et al., 2003. The DsbA signal sequence directs efficient, cotranslational export of passenger proteins to the Escherichia coli periplasm via the signal recognition particle pathway. Journal of Bacteriology, 185(19), pp.5706–5713.</li>
 +
                        <li>Steiner, D. et al., 2006. Signal sequences directing cotranslational translocation expand the range of proteins amenable to phage display. Nature biotechnology, 24(7), pp.823–831.</li>
 +
                        <li>Božić, N. et al., 2013. The DsbA signal peptide-mediated secretion of a highly efficient raw-starch-digesting, recombinant α-amylase from Bacillus licheniformis ATCC 9945a. Process Biochemistry, 48(3), pp.438–442.</li>
 +
                        <li>Zhang, G., Brokx, S. & Weiner, J.H., 2006. Extracellular accumulation of recombinant proteins fused to the carrier protein YebF in Escherichia coli. Nature biotechnology, 24(1), pp.100–104.</li>
 +
                        <li>Fisher, A.C. et al., 2011. Production of secretory and extracellular N-linked glycoproteins in Escherichia coli. Applied and Environmental Microbiology, 77(3), pp.871–881.</li>
 +
                        <li>Hwang, I.Y. et al., 2014. Reprogramming microbes to be pathogen-Seeking killers. ACS Synthetic Biology, 3(4), pp.228–237.</li>
 +
                        <li>Dramatic rise seen in antibiotic use. Available from: <a href="http://www.nature.com/news/dramatic-rise-seen-in-antibiotic-use-1.18383?WT.mc_id=TWT_NatureNews">http://www.nature.com/news/dramatic-rise-seen-in-antibiotic-use-1.18383?WT.mc_id=TWT_NatureNews</a> [17/09/2015]</li>
 +
                    </ol>
 
                 </div>
 
                 </div>
 
             </div>
 
             </div>
 
             <div class="col-md-3 contents-sidebar">
 
             <div class="col-md-3 contents-sidebar">
−
                 <ul id="sidebar" class="nav nav-stacked sm-hidden xs-hidden" data-spy="affix">
+
                 <ul id="sidebar" class="nav nav-stacked" data-spy="affix">
 +
                    <li><a href="#overview">Overview</a></li>
 +
                    <li><a href="#problem">The Problem</a></li>
 +
                    <li><a href="#antibio">The Problem with Antibiotics</a></li>
 +
                    <li><a href="#biofilms">Biofilms</a></li>
 +
                    <li><a href="#utis">UTIs</a></li>
 +
                    <li>
 +
                        <a href="#solution"></a>
 +
                        <ul class="nav nav-stacked">
 +
                            <li><a href="#solution-overview">Overview</a></li>
 +
                            <li><a href="#solution-degrading-biofilm">Degrading the Biofilm</a></li>
 +
                            <li>
 +
                                <a href="#solution-killing-bacteria">Killing the Bacteria</a>
 +
                                <ul class="nav nav-stacked">
 +
                                    <li><a href="#solution-killing-bacteria-art175">Art-175</a></li>
 +
                                    <li><a href="#solution-killing-bacteria-mccs">MccS</a></li>
 +
                                </ul>
 +
                            </li>
 +
                            <li>
 +
                                <a href="#solution-secreting">Secreting the Proteins</a>
 +
                                <ul class="nav nav-stacked">
 +
                                    <li><a href="#solution-sectreting-dsba">DspA</a></li>
 +
                                    <li><a href="#solution-sectreting-yebf">YebF</a></li>
 +
                                    <li><a href="#solution-secreting-fla">Fla</a></li>
 +
                                </ul>
 +
                            </li>
 +
                        </ul>
 +
                    </li>
 
                     <li>
 
                     <li>
−
                         <a href="#overview">Overview</a>
+
                         <a href="#results">Results</a>
 
                         <ul class="nav nav-stacked">
 
                         <ul class="nav nav-stacked">
−
                             <li><a href="#overview-what">What?</a></li>
+
                             <li>
−
                            <li><a href="#overview-why">Why?</a></li>
+
                                <a href="#results-antimicrobials">Antimicrobials</a>
−
                             <li><a href="#overview-how">How?</a></li>
+
                                <ul class="nav nav-stacked">
 +
                                    <li><a href="#results-antimicrobials-art175"></a></li>
 +
                                    <li><a href="results-antimicrobials-mccs"></a></li>
 +
                                </ul>
 +
                             </li>
 +
                            <li>
 +
                                <a href="#results-antibiofilms">Anitbiofilms</a>
 +
                                <ul class="nav nav-stacked">
 +
                                    <li><a href="#results-antibiofilms-dspb"></a></li>
 +
                                </ul>
 +
                            </li>
 
                         </ul>
 
                         </ul>
 
                     </li>
 
                     </li>

Revision as of 12:12, 18 September 2015

Description

Overview

"Years from now we will treat most infections with bacteria and not antibiotics."

Professor James Malone-Lee
Barlow Professor of Geriatric Medicine

A solution is urgently needed for the increasing number of infections caused by antibiotic-resistant bacteria. The engineering of bacterial cells to fight human pathogens is a promising alternative to administering traditional antibiotics. Our project involves the use of synthetic biology to engineer living therapeutics that have the potential to treat urinary tract infections (UTIs), which are a major public health concern in developed countries. This is largely due to growing antimicrobial resistance (AMR).

The problem

  • Antibiotics have negative side effects and antimicrobial resistance is a growing problem
  • UTIs are the most common hospital-acquired infection and the bacteria that cause them are frequently resistant to antimicrobials
  • AMR in UTIs is caused by biofilms
  • Biofilms are currently estimated to be responsible for over 65% of all hospital-acquired infections
  • Current UTI treatments are ineffective and fail to prevent recurrent infections

Problem with antibiotics

Antibiotic use is associated with numerous negative side effects, allergies and reactions. The most common side effects of antibiotics all impact the digestive system and occur in around one in ten people. Around one person in fifteen has an allergic reaction to antibiotics, especially penicillin and cephalosphorins [10]. Half of the patients we spoke to during our project wanted us to find an alternative to using antibiotics, owing to the severity of the negative side effects that they experience.

Despite their negative side effects, antibiotics have been used so widely and for so long that the targeted microbes have adapted to become resistant, reducing the effectiveness of the drugs. A vicious cycle ensues in which ineffective antibiotic treatments leads to overprescription and overexposure, which amplifies the problem of AMR. Global antibiotic consumption grew by 30% between 2000 and 2010. [27] Described by the Chief Medical Officer of England as “a threat equal to that of terrorism”, the growing resistance to antibiotics is hindering the effective prevention and treatment of an ever increasing range of infections.

Antimicrobial resistance poses a catastrophic threat. If we don't act now, any one of us could go into hospital in 20 years for minor surgery and die because of an ordinary infection that can't be treated by antibiotics.

Professor Dame Sally Davies
Chief Medical Officer
March 2013

The World Health Organisation’s (WHO) antimicrobial resistance Global Report on Surveillance, reports increasing worldwide incidences of AMR, in particular antibacterial resistance (ABR). This highlights very high rates of resistance in bacteria that cause common healthcare associated and community-acquired infections, such as UTIs [1]. UTIs account for over 7 million doctor visits per year. Catheter associated UTIs (CAUTIs) are the most commonly acquired infection in hospitals, and there is a high incidence of ABR in the bacteria that cause UTIs globally [2].

Biofilms

Biofilms are aggregates of surface-associated microorganisms that are encased in a matrix of highly-hydrated extracellular polymeric substances (EPS), which include extracellular polysaccharides, extracellular DNA, as well as proteins [6]. Van Leeuwenhoek, using his simple microscopes in 1684, first observed microorganisms on tooth surfaces and can be credited with the discovery of microbial biofilms. "The number of these animalcules in the scurf of a man's teeth are so many that I believe they exceed the number of men in a kingdom." - Leeuwenhoek

We now know a great deal more about biofilms. Environmental changes are responsible for the transition from planktonic growth to biofilm [13] and cause changes in the expression of surface molecules, virulence factors, and metabolic status. This allows the bacteria to acquire properties that enable their survival in unfavourable conditions [14,15], such as in the presence of antibiotics. The low nutrient and oxygen levels at the bottom of the biofilm give rise to metabolically-inactive bacteria. As such, these persister cells are rendered unsusceptible to most traditional antibiotics, which rely on bacterial metabolism to exert cell-killing effect [7].

UTIs

Biofilms are currently estimated to be responsible for over 65% of nosocomial infections and 80% of all microbial infections [16]. Bacterial biofilms play an important role in UTIs. UTIs are caused by the pathogenic invasion of the urinary tract, which causes an inflammatory response of the urothelium. It is estimated that approximately 40% of women have had a UTI at some time in their lives [10]. UTIs may be caused by a variety of different organisms, most commonly bacteria. The most frequent cause of UTI in adult women is Escherichia coli, accounting for approximately 85% of community-acquired UTIs and 25-50% of hospital-acquired UTIs. Nosocomial infections may involve more aggressive organisms such as Pseudomonas aeruginosa and Enterobacter species.

The Solution

  • Break down bacterial biofilms to liberate the bacteria encased within and reduce the dose of antibiotics required
  • Breaking down bacterial biofilms and kill the bacteria encased within to provide an alternative to antibiotics
Our solution is focused on providing a treatment for UTIs because conventional antibiotics are unable to treat these and other biofilm-associated infections. Given the prevalence of such infections, there is a growing need for alternative therapeutic agents that can specifically degrade biofilms and kill the bacteria encased within. The use of synthetic biology to produce enzymes is the most effective way to achieve this specificity based on current technology. Our solution aims to investigate how bacterial biofilm disrupting proteins and antimicrobial proteins can be exported from E. coli and subsequently retain their antibiofilm/antimicrobial function. Using this secretion device we seek to create a system that offers persistent protection against biofilm formation.

We have designed a device that can exert antibiofilm and antibacterial activity against E. coli and P. aeruginosa, the two leading causes of CAUTIs [4]. A nonpathogenic laboratory strain of E. coli is used as the expression host for the production of these enzymes as a proof-of-concept. The antibiofilm enzymes that we are using are Dispersin B and Micrococcal DNase, and the antibacterial proteins that we are using are Art-175 and Microcin S.

Degrading the biofilm

Prof. Malone-Lee stressed to us that sensitivity is a greater problem than complete antimicrobial resistance. “Many more strains of bacteria are just insensitive to low doses of antibiotics, many can be overcome by high doses over long periods of time. Resistance is definitely not absolute.” Breaking down the biofilm increases the sensitivity of the bacteria embedded within it. Planktonic bacteria are metabolically active and are thus prone to antibiotics, meaning that lower doses are required.

DspB (BBa_K1659200) is an enzyme produced by Aggregatibacter actinomycetemcomitans, a species of bacteria found in the human oral cavity that grows almost exclusively in the form of biofilms. Structural analysis of Dispersin B showed that the enzyme only works specifically against the β-1,6-glycosidic linkages found in poly-N-acetylglucosamine (PGA), which is a polysaccharide structural element found in the biofilms of E. coli but not in P. aeruginosa. An additional enzyme would need to be used to target the polysaccharide component of P. aeruginosa biofilms.

Micrococcal DNase (BBa_K1659300) is an endo-exonuclease that non-specifically catalyzes the hydrolysis of single- and double-stranded DNA under basic conditions and in the presence of Ca2+ ions, and is known to be able to speed up DNA hydrolysis by up to 1016 times [17]. We are using DNase to break down the extracellular DNA component of biofilms.

Killing the bacteria

Although ABR is not absolute, it does pose a very big threat to the effective treatment of many infections. The insensitivity of bacteria to antibiotics can also be attributed to the increasing ABR. As described above, antibiotics also have many side effects that reduce patient quality of life and decrease the likelihood of completing a course of antibiotics. With all of this in mind, our solution does not only break down the biofilm, but also kills the bacteria embedded within so as to provide an alternative to antibiotics.

Art-175

Art-175 (BBa_K1659000) derive their name from “artificial endolysins”. Endolysins are bacteriophage-encoded peptidoglycan hydrolases that pass through the cytoplasmic membrane, degrading the peptidoglycan layer and inducing the lysis of the infected cell.

MccS

MccS (BBa_K1659000) is a type of microcin, a subclass of antibacterial proteins known as bacteriocins. Microcins are small, enterobacteria-produced bacteriocins that exert antibacterial activity against closely-related species, and MccS is produced by E. coli present in the probiotic drug Symbioflor 2 that has been shown to successfully treat gastrointestinal disorders.

For more information, please visit our Parts page.

Current clinically-relevant pathogens have not been seen to exhibit resistance against our antibacterial proteins of choice. Art-175 has been experimentally shown to be not susceptible to resistance development, likely because it targets the structural element of the bacterial cell wall that is highly conserved across species and difficult to mutate [8]. The mechanism by which Microcin S exerts antibacterial activity is still currently unknown, but no bacterial strains except for the original strain of probiotic E. coli which produces Microcin S has been shown to be resistant to it thus far [9].

Secreting the proteins

The proven secretion of folded, functional proteins across both bacterial cell membranes is a challenge for present day microbiologists. Our solution requires that we can export DspB, DNase, Art-175 and MccS out of the expression host and into the local biofilm environment. To achieve this, signal sequences are fused to the enzymes to target them for export through natural E. coli secretion pathways. Using this mechanism we can direct our anti-biofilm and antimicrobial agents at a biofilm infected surface as they are being produced.

DsbA

DsbA is a oxidoreductase protein found predominantly in Gram-negative bacteria, which functions as a protein-folding factor [19][20]. The 2-19 peptide sequence of DsbA is a signal sequence that can direct passenger proteins for co-translational export via the signal recognition particle (SRP) pathway [21][22]. It has recently been shown that the DsbA signal sequence is capable of mediating passenger protein secretion under a selection of different induction temperatures [23].

Parts: BBa_K1659002, BBa_K1659201,BBa_K1659301

YebF

YebF is a 13kDa protein of unknown function that is perhaps the only protein that has been conclusively documented to be secreted into the extracellular medium by a laboratory E. coli strain. At the N-terminus, YebF has a 2.2 kDa sec-leader sequence which mediates its translocation through the bacterial inner membrane via the Sec pathway, and is cleaved upon translocation into the periplasm to give the 10.8 kDa "mature" form [24]. Export from periplasm into the extracellular space takes places via the Omp pathway. YebF has been used successfully to mediate the secretion of recombinant proteins [25][26].

Part: BBa_K1659003

Fla

Flagellin are the constituent subunits of the helical filament substructure of bacterial flagella. In the flagellar-building process, flagellin are exported out of the cell sequentially by the flagellum-specific export apparatus. F. Vonderviszt et al. demonstrated through their work that the signal sequence responsible for allowing the flagellar export system to identify and export Salmonella flagellin is its 26-47 amino acid residue segment [18].

Part: BBa_K1659001

Results

Antimicrobials

Art-175

MccS

Antibiofilms

DspB

Conclusion

Future

Our modelling of diffusion out of the biobeads showed that we would need too great a number of biobeads for this to be realistic design approach. To overcome this problem we would need unrealistically efficient enzymes or unrealistically high protein synthesis rates. The other way around this is to create a system that provides a high local concentration of antibiofilm/antimicrobial agents at the point that is needed.

References

  1. Global Report on Surveillance of Antimicrobial Resistance: 2014. WHO.
  2. Johnson, J.R., 2004. Laboratory diagnosis of urinary tract infections in adult patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 39(6), p.873; author reply 873–874.
  3. Zalewska-Piatek, B. et al., 2013. Biochemical characteristic of biofilm of uropathogenic Escherichia coli Dr+ strains. Microbiological Research, 168, pp.367–378.
  4. Sievert, D.M. et al., 2013. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America, 34(1), pp.1–14. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23221186.
  5. Fux, C. a. et al., 2005. Survival strategies of infectious biofilms. Trends in Microbiology, 13(1), pp.34–40.
  6. Flemming, H.-C. & Wingender, J., 2010. The biofilm matrix. Nature reviews. Microbiology, 8(9), pp.623–633. Available at: http://dx.doi.org/10.1038/nrmicro2415.
  7. Høiby, N. et al., 2010. Antibiotic resistance of bacterial biofilms. International Journal of Antimicrobial Agents, 35(4), pp.322–332.
  8. Briers, Y. et al., 2014. Art-175 is a highly efficient antibacterial against multidrug-resistant strains and persisters of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 58(7), pp.3774–3784.
  9. Gunzer, F., 2013. Bacterially-formed microcin S, a new antimicrobial peptide, effective against pathogenic microorganisms, e.g. enterohaemorrhagic Escherichia coli (EHEC), European Patent EP2557163A1.
  10. Antibiotics - Side effects. Avaolable from: http://www.nhs.uk/Conditions/Antibiotics-penicillins/Pages/Side-effects.aspx [5/06/2015]
  11. C. M. Kunin, “Urinary tract infections in females,” Clinical Infectious Diseases, vol. 18, no. 1, pp. 1–12, 1994.
  12. J. W. Warren, “Catheter-associated urinary tract infections,” Infectious Disease Clinics of North America, vol. 11, no. 3, pp. 609–622, 1997
  13. A. P. Lenz, K. S. Williamson, B. Pitts, P. S. Stewart, and M. J. Franklin, “Localized gene expression in Pseudomonas aeruginosa biofilms,” Applied and Environmental Microbiology, vol. 74, no. 14, pp. 4463–4471, 2008.
  14. L. Zhang and T. Mah, “Involvement of a novel efflux system in biofilm-specific resistance to antibiotics,” Journal of Bacteriology, vol. 190, no. 13, pp. 4447–4452, 2008.
  15. J. Klebensberger, A. Birkenmaier, R. Geffers, S. Kjelleberg, and B. Philipp, “SiaA and SiaD are essential for inducing autoaggregation as a specific response to detergent stress in Pseudomonas aeruginosa,” Environmental Microbiology, vol. 11, no. 12, pp. 3073–3086, 2009
  16. U. Römling and C. Balsalobre, “Biofilm infections, their resilience to therapy and innovative treatment strategies,” Journal of Internal Medicine, vol. 272, no. 6, pp. 541–561, 2012
  17. Hale, S.P., Poole, L.B. & Gerlt, J. a, 1993. Mechanism of the reaction catalyzed by staphylococcal nuclease: identification of the rate-determining step. Biochemistry, 32(29), pp.7479–7487
  18. Vondervizst, F., Sajó, R., Dobó, J., & Závodszky, P. (2012). The Use of a Flagellar Export Signal for the Secretion of Recombinant Proteins in Salmonella. In: Recombinant Gene Expression - Reviews and Protocols, Methods in Molecular Biology, 824, 131-143.
  19. Guddat, L.W., Bardwell, J.C. & Martin, J.L., 1998. Crystal structures of reduced and oxidized DsbA: investigation of domain motion and thiolate stabilization. Structure (London, England : 1993), 6(6), pp.757–767.
  20. Heras, B. et al., 2009. DSB proteins and bacterial pathogenicity. Nature reviews. Microbiology, 7(3), pp.215–225.
  21. Schierle, C.F. et al., 2003. The DsbA signal sequence directs efficient, cotranslational export of passenger proteins to the Escherichia coli periplasm via the signal recognition particle pathway. Journal of Bacteriology, 185(19), pp.5706–5713.
  22. Steiner, D. et al., 2006. Signal sequences directing cotranslational translocation expand the range of proteins amenable to phage display. Nature biotechnology, 24(7), pp.823–831.
  23. Božić, N. et al., 2013. The DsbA signal peptide-mediated secretion of a highly efficient raw-starch-digesting, recombinant α-amylase from Bacillus licheniformis ATCC 9945a. Process Biochemistry, 48(3), pp.438–442.
  24. Zhang, G., Brokx, S. & Weiner, J.H., 2006. Extracellular accumulation of recombinant proteins fused to the carrier protein YebF in Escherichia coli. Nature biotechnology, 24(1), pp.100–104.
  25. Fisher, A.C. et al., 2011. Production of secretory and extracellular N-linked glycoproteins in Escherichia coli. Applied and Environmental Microbiology, 77(3), pp.871–881.
  26. Hwang, I.Y. et al., 2014. Reprogramming microbes to be pathogen-Seeking killers. ACS Synthetic Biology, 3(4), pp.228–237.
  27. Dramatic rise seen in antibiotic use. Available from: http://www.nature.com/news/dramatic-rise-seen-in-antibiotic-use-1.18383?WT.mc_id=TWT_NatureNews [17/09/2015]